BioNTech to pay $1.2 billion over vaccine royalties

Penn to receive $467M under settlement with BioNTech over Covid-19 vaccine royalties
Penn has reached an agreement to resolve a dispute over Covid-19 royalties the Philadelphia university alleged it was owed.
BioNTech enters settlement with US agency, UPenn over COVID vaccine royalties
BioNTech has entered into two separate settlement agreements with the U.S. National Institutes of Health and the University of Pennsylvania over the payment of royalties related to its COVID-19 vaccine,
BioNTech inks $1B settlements with NIH and Penn to resolve COVID vaccine royalty claims
BioNTech (NASDAQ:BNTX) announced Friday two separate agreements worth more than $1B with the National Institutes of Health (NIH) and the University of Pennsylvania to resolve royalty and other claims related to sales of its COVID-19 vaccine developed with Pfizer (PFE).
COVID: BioNTech to pay $1.2 billion over vaccine royalties
German pharmaceutical company BioNTech has agreed to pay a combined sum of more than $1.2 billion to resolve separate disputes over royalty payments related to its COVID-19 vaccine.
BioNTech to pay $791.5M in settlement agreement with the NIH
In a regulatory filing, BioNTech (BNTX) said, “BioNTech previously disclosed that it was in discussions with the National Institutes of Health concerning royalties and other related amounts allegedly owed on sales of the Company’s,
BioNTech to Pay Up to $1.26B in Covid-19 Vaccine Settlements With NIH, Penn
BioNTech has agreed to pay $1.26 billion across two separate settlements with the National Institutes of Health and the University of Pennsylvania tied to royalties for its Covid-19 vaccine. The German developer of RNA vaccines and immunotherapies,
Hosted on MSN17h
BioNTech Stock In Focus After $791.5M Settlement With NIH: Retail Cautious
Shares of BioNTech slipped 0.83% in after-hours trading on Friday after the company said it would pay $791.5 million in a ...
NIH settlement ‘manageable headwind’ for BioNTech, Pfizer, says Morgan Stanley
Morgan Stanley analyst Terence Flynn notes that BioNTech (BNTX) announced last week that it had reached a settlement agreement with the ...
Pharmaceutical Technology3h
BNT-321 by BioNTech for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
BNT-321 is under clinical development by BioNTech and currently in Phase I for Pancreatic Ductal Adenocarcinoma.
BioNTech's Big Moves: $1.2 Billion Settlements and a Game-Changing Cancer Bet
Settling royalty disputes and acquiring Biotheus, BioNTech reshapes its future in vaccines and oncology innovation.
gulftoday1d
BioNTech settles millions’ royalty issue
Pharma majors like BioNTech in Germany and Pfizer in the United States have made profits in billions of dollars in selling ...
BioNTech SE ADR rises Friday, outperforms market
BioNTech SE ADR closed $17.54 below its 52-week high ($131.49), which the company achieved on September 17th.
Daily1d
BioNTech enters settlement with US National Institutes of Health, University of Pennsylvania
Bengaluru: German biotechnology company BioNTech has reached two separate settlement agreements with the U.S. National ...